[{"orgOrder":0,"company":"NaviFUS","sponsor":"NaviFUS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NaviFUS \/ NaviFUS","highestDevelopmentStatusID":"7","companyTruncated":"NaviFUS \/ NaviFUS"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Sulfur Hexafluoride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lumason is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 06, 2024

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Lumason is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioblastoma.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 26, 2024

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : NaviFUS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of California, Los Angeles

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          University of California, Los Angeles

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Lumason is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stroke.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 28, 2017

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Burl Concepts

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Children's Hospital of Philadelphia

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Children's Hospital of Philadelphia

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Lumason is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Developmental Dysplasia of the Hip.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 11, 2017

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : Bracco | Pediatric Orthopaedic Society of North America

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lumason is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Coronary Artery Disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 17, 2015

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lumason is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Coronary Artery Disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 13, 2015

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Sulfur Hexafluoride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rhegmatogenous Retinal Detachment, Autosomal Dominant.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 09, 2014

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Sonovue is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 27, 2014

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Sonovue is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 01, 2011

                          Lead Product(s) : Sulfur Hexafluoride

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank